IRONWOOD PHARMACEUTICALS INC Form SC 13G/A October 07, 2010

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Schedule 13G

Under the Securities Exchange Act of 1934

(Amendment No.:1)*

Name of issuer: Ironwood Pharmaceuticals Inc

Title of Class of Securities: Common Stock

CUSIP Number: 46333X108

Date of Event Which Requires Filing of this Statement: September 30, 2010

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

(X) Rule 13d-1(b)

Edgar Filing: IRONWOOD PHARMACEUTION	CALS INC - Form SC 13G/A
() Rule 13d-1(c)	
() Rule 13d-1(d)	
*The remainder of this cover page shall be filled out for a reporting the subject class of securities, and for any subsequent amendment codisclosures provided in a prior cover page.	
The information required in the remainder of this cover page shall a Section 18 of the Securities Exchange Act of 1934 ("Act") or otherw. Act but shall be subject to all other provisions of the Act (however, second content of the Act (however, se	rise subject to the liabilities of that section of the
(Continued on the following page(s))	

13G
CUSIP No.: 46333X108
1. NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
Vanguard Specialized Funds - Vanguard Health Care Fund - 23-2439149
2. CHECK THE APPROPRIATE [LINE] IF A MEMBER OF A GROUP
2. CHECK THE ALTROPHITE [ELIVE] II TAMEMBER OF A GROOT
A. B. <u>X</u>
3. SEC USE ONLY
4. CITIZENSHIP OF PLACE OF ORGANIZATION
Delaware
(For questions 5-8, report the number of shares beneficially owned by each reporting person with:)
5. SOLE VOTING POWER

Edgar Filing: IRONWOOD PHARMACEUTICALS INC - Form SC 13G/A 2,000,000 6. SHARED VOTING POWER 7. SOLE DISPOSITIVE POWER 8. SHARED DISPOSITIVE POWER 9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 2,000,000 10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES N/A

11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

4.65%

12. TYPE OF REPORTING PERSON

IV

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Act of 1934
Check the following [line] if a fee is being paid with this statement N/A
Item 1(a) - Name of Issuer:
Ironwood Pharmaceuticals Inc
Item 1(b) - Address of Issuer's Principal Executive Offices:
301 BINNEY STREET
CAMBRIDGE, MASSACHUSETTS 02142
Item 2(a) - Name of Person Filing:

Vanguard Specialized Funds - Vanguard Health Care Fund - 23-2439149

<u>Item 2(b) – Address of Principal Business Office or, if none, residence:</u>

100 Vanguard Blvd.
Malvern, PA 19355
<u>Item 2(c) – Citizenship:</u>
Delaware
Item 2(d) - Title of Class of Securities:
Common Stock
Common Stock
<u>Item 2(e) - CUSIP Number</u>
46333X108
Item 3 - Type of Filing:
This statement is being filed pursuant to Rule 13d-1. Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8).
Item 4 - Ownership:
(a) Amount Beneficially Owned:
2,000,000

(b) Percent of Class:

4.65%

(c) Number of shares as to which such person has:
(i) sole power to vote or direct to vote: 2,000,000
(ii) shared power to vote or direct to vote:
(iii) sole power to dispose of or to direct the disposition of:
(iv) shared power to dispose or to direct the disposition of:
Comments:
Item 5 - Ownership of Five Percent or Less of a Class:
Not Applicable
<u>Item 6 - Ownership of More Than Five Percent on Behalf of Another Person:</u>
Not applicable
<u>Item 7 - Identification and Classification of the Subsidiary Which Acquired The Security Being Reported on by the Parent Holding Company</u> :
Not Applicable

<u>Item 8 - Identification and Classification of Members of Group:</u>
Not applicable
<u>Item 9 - Notice of Dissolution of Group:</u>
Not applicable
<u>Item 10 - Certification:</u>
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired in the ordinary course of business and were not acquired for the purpose of and do not have the effect of changing or influencing the control of the issuer of such securities and were not acquired in connection with or as a participant in any transaction having such purpose or effect.
<u>Signature</u>
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Date: 10/7/2010
By <u>/s/ F. William McNabb III*</u>

F. William McNabb III

President and Chief Executive Officer

*By: /s/ Glenn Booraem

Glenn Booream, pursuant to a Power of Attorney filed on January 29, 2010, see File Number 005-81485, Incorporated by Reference